IDENTIFICATION OF NEURAL DEFECTS ASSOCIATED WITH THE NUCLEOSOM AL ASSEMBLY PROTEIN 1L2 GENE

摘要

A method for screening neural system defects in a human comprises: (A) providing chromosomal material from the human; (B) detecting a modification of the NAP1L2 gene in the chromosomal material, wherein the modification is selected from a) substitution, b) dele-tion, c) frame-shift, or d) insertion that causes a loss of biological function in the NAP1L2 gene; and (C) correlating the modification of the gene with a potential for a neural system defect. The method can also be practiced with the mouse Nap1L2 gene.